Id: acc4689
Group: 1sens
Protein: SNAP-25
Gene Symbol: Snap25
Protein Id: P60880
Protein Name: SNP25_HUMAN
PTM: phosphorylation
Site: Ser187
Site Sequence: IDRIMEKADSNKTRIDEANQR
Disease Category: Nervous system diseases
Disease: Epilepsy
Disease Subtype: synaptic plasticity
Disease Cellline:
Disease Info:
Drug: BRV
Drug Info: "BRV is a drug, which may have specific therapeutic effects in relevant medical fields."
Effect: modulate
Effect Info: "After more than 30 days of BRV treatment, it was found that BRV improved the overexpression of synaptic vesicle protein 2A (SV2A), rescued synaptic dysfunction in the hippocampus, and alleviated the abnormal phosphorylation of SNAP–25 at Ser187 during long-term potentiation (LTP) induction."
Note:
Score: 4.0
Pubmed(PMID): 32407277
Sentence Index:
Sentence:

Sequence & Structure:

MAEDADMRNELEEMQRRADQLADESLESTRRMLQLVEESKDAGIRTLVMLDEQGEQLERIEEGMDQINKDMKEAEKNLTDLGKFCGLCVCPCNKLKSSDAYKKAWGNNQDGVVASQPARVVDEREQMAISGGFIRRVTNDARENEMDENLEQVSGIIGNLRHMALDMGNEIDTQNRQIDRIMEKADSNKTRIDEANQRATKMLGSG

Select PDB:

Known Drugs:

source: Multi-Sources

(see table)

Target Drug name MOA Phase Status Disease Source
SNAP25 BOTULINUM TOXIN TYPE A Synaptosomal nerve-associated protein 25 (SNAP-25) hydrolytic enzyme 4 - skin aging EMA
SNAP25 DAXIBOTULINUMTOXINA Synaptosomal nerve-associated protein 25 (SNAP-25) inhibitor 4 - skin aging FDA
SNAP25 PRABOTULINUMTOXIN A Synaptosomal-associated protein 25 proteolytic enzyme 4 - skin aging FDA
SNAP25 BOTULINUM TOXIN TYPE A Synaptosomal nerve-associated protein 25 (SNAP-25) hydrolytic enzyme 4 - urgency urinary incontinence DailyMed
SNAP25 BOTULINUM TOXIN TYPE A Synaptosomal nerve-associated protein 25 (SNAP-25) hydrolytic enzyme 4 - overactive bladder DailyMed
SNAP25 BOTULINUM TOXIN TYPE A Synaptosomal nerve-associated protein 25 (SNAP-25) hydrolytic enzyme 4 - migraine disorder DailyMed
SNAP25 ONABOTULINUMTOXINA Synaptosomal-associated protein 25 inhibitor 3 Completed nervous system disease ClinicalTrials
ClinicalTrials
SNAP25 INCOBOTULINUMTOXINA Synaptosomal-associated protein 25 inhibitor 3 Completed stroke ClinicalTrials
SNAP25 ONABOTULINUMTOXINA Synaptosomal-associated protein 25 inhibitor 3 Completed stroke ClinicalTrials
ClinicalTrials
ClinicalTrials
ClinicalTrials
ClinicalTrials
SNAP25 ONABOTULINUMTOXINA Synaptosomal-associated protein 25 inhibitor 3 Recruiting stroke ClinicalTrials
SNAP25 ONABOTULINUMTOXINA Synaptosomal-associated protein 25 inhibitor 3 Unknown status stroke ClinicalTrials
ClinicalTrials
SNAP25 ONABOTULINUMTOXINA Synaptosomal-associated protein 25 inhibitor 3 Completed essential tremor ClinicalTrials
SNAP25 ONABOTULINUMTOXINA Synaptosomal-associated protein 25 inhibitor 3 Terminated prostatitis ClinicalTrials
SNAP25 ONABOTULINUMTOXINA Synaptosomal-associated protein 25 inhibitor 3 Completed pain ClinicalTrials
ClinicalTrials
SNAP25 ONABOTULINUMTOXINA Synaptosomal-associated protein 25 inhibitor 3 Recruiting pain ClinicalTrials
SNAP25 ONABOTULINUMTOXINA Synaptosomal-associated protein 25 inhibitor 3 Terminated pain ClinicalTrials
SNAP25 ONABOTULINUMTOXINA Synaptosomal-associated protein 25 inhibitor 3 Not yet recruiting contracture ClinicalTrials
SNAP25 ONABOTULINUMTOXINA Synaptosomal-associated protein 25 inhibitor 3 Completed neuropathy ClinicalTrials
SNAP25 ONABOTULINUMTOXINA Synaptosomal-associated protein 25 inhibitor 3 Terminated skin aging ClinicalTrials
SNAP25 ONABOTULINUMTOXINA Synaptosomal-associated protein 25 inhibitor 3 Completed skin aging ClinicalTrials
ClinicalTrials
ClinicalTrials
ClinicalTrials
ClinicalTrials
SNAP25 BOTULINUM TOXIN TYPE A Synaptosomal nerve-associated protein 25 (SNAP-25) hydrolytic enzyme 3 Completed skin aging ClinicalTrials
SNAP25 ONABOTULINUMTOXINA Synaptosomal-associated protein 25 inhibitor 3 Withdrawn neuropathic pain ClinicalTrials
SNAP25 ONABOTULINUMTOXINA Synaptosomal-associated protein 25 inhibitor 3 Unknown status severe cutaneous adverse reaction ClinicalTrials
ClinicalTrials
SNAP25 ONABOTULINUMTOXINA Synaptosomal-associated protein 25 inhibitor 3 Completed urgency urinary incontinence ClinicalTrials
SNAP25 ONABOTULINUMTOXINA Synaptosomal-associated protein 25 inhibitor 3 Terminated urgency urinary incontinence ClinicalTrials

Note: Only show clinically investigational or approved drugs with protein targets.

Protein Tractability:

source: Open Targets
Small molecule
Antibody
PROTAC
Other modalities
Approved Drug
Advanced Clinical
Phase 1 Clinical
Structure with Ligand
High-Quality Ligand
High-Quality Pocket
Med-Quality Pocket
Druggable Family
Approved Drug
Advanced Clinical
Phase 1 Clinical
UniProt loc high conf
GO CC high conf
UniProt loc med conf
UniProt SigP or TMHMM
GO CC med conf
Human Protein Atlas loc
Approved Drug
Advanced Clinical
Phase 1 Clinical
Literature
UniProt Ubiquitination
Database Ubiquitination
Half-life Data
Small Molecule Binder
Approved Drug
Advanced Clinical
Phase 1 Clinical

PTM Intensity:

source: CPTAC

No data.

PTM-Disease Association:

source: PTMD

No data.

PTM-Drug Perturbation Response:

source: DecryptM

No data.

Function score:

source: funscoR

No data.

Cross Links: